SPOTLIGHT: NIH starts Tykerb vs. Herceptin bout

It's a head-to-head matchup. The National Institutes of Health has launched an 8,000-patient trial pitting GlaxoSmithKline's Tykerb against Genentech's Herceptin in aggressive breast cancer. Meanwhile, GSK is poised to launch its med in the U.K. as Tyverb. Report | Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.